Kymera Investor Presentation Deck
●
●
●
PK and PD profiles in DL1-4* consistent with
preclinical data supporting once every three-week
dosing regimen
●
●
Desired Translation of PK, PD and Safety of KT-413
●
KT-413 achieved dose-dependent degradation of
up to 70% IRAK4 and 96-100% Ikaros and Aiolos in
PBMC after a single dose
Consistent degradation in blood and tumor
Profile that in preclinical species led to robust
antitumor activity in MYD88 mutant tumors
The most common adverse events were fatigue,
cough and pyrexia.** No DLTs or drug-related
neutropenia were observed in the study.
Expect to be at potentially clinically active profiles
at DL3-4 and beyond.
*DL1-3 have been completed and DL4 remains open to accrual.
**AEs related to KT-413 were all Grade 1 and 2; SAEs (Gr. 4 sepsis and Gr. 4 lung infection)
reported in one patient in DL3 occurred outside of the DLT window at the end of Cycle 2 in the
setting of disease progression.
KYMERA ©2023 KYMERA THERAPEUTICS, INC.
Potential to be First Precision Medicine
in DLBCL to Target a Genetically-
defined Population (MYD88MT)
Profound antitumor activity in preclinical models
both in single agent and combination
Clinical strategy in place to enable accelerated
approval:
Monotherapy
MYD88MT DLBCL for most direct path to registration
Other MYD88MT lymphomas of interest include PCNSL, WM
Combinations
With SOC agents in MYD88MT DLBCL to enable earlier line
therapy
PAGE 40View entire presentation